Analyst Price Target is $8.00
▲ +268.66% Upside Potential
This price target is based on 0 analysts offering 12 month price targets for Microbot Medical in the last 3 months. The average price target is $8.00, with a high forecast of $8.00 and a low forecast of $8.00. The average price target represents a 268.66% upside from the last price of $2.17.
Current Consensus is
The current consensus among 0 contributing investment analysts is to n/a stock in Microbot Medical. This rating has held steady since August 2021, when it changed from a Buy consensus rating.
Microbot Medical, Inc. is a pre-clinical medical device company engaged in the research, design, development, and commercialization of micro-robotics assisted medical technologies. The firm carries out its operations through the ViRob and TipCat platforms. The ViRob platform technology is an autonomous crawling micro-robot that can be controlled remotely or within the body. It makes use of the Self-Cleaning Shunt, a robotic system designed as the ventricular catheter portion of a Cerebrospinal Fluid shunt system and is mainly used for the treatment of hydrocephalus and Normal Pressure Hydrocephalus. The TipCat platform, a self-propelling, flexible, and semi-disposable endoscope, provides see-and-treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. The company was founded by Harel Gadot, Moshe Shoham, and Yosseph Bornstein on August 2, 1988 and is headquartered in Hingham, MA.